Fresenius SE (FRE.DE) Buy, Sell or Hold

Fresenius SE (FRE.DE)

33.24

-0.00 (0.00%)

as of Aug 29, 2024, 4:00:00 am Market Open.

5 watching

PAST TOP PICK

(A Top Pick Jul 31/18, Down 34%) Sold it 6 months after picking the stock. Had a big drop in the forth quarter and sold it in a risk management point of view. It's the global leader in kidney diagnosis treatment so the business isn't going away. Still likes the company. If it was to drop a little bit further he would consider buying it back. A good company, just had an unfortunate earnings report during Q4 in December, a really bad timing, if they had it in January we wouldn't have seen that down.

Wealthica Track your Stocks in your Watch List

COMMENT

This is the parent of Fresenius Medical, which operates dialysis clinics. The parent company also owns hospitals and a project management business. The dividend has been growing about 12% per year for about 15 years. (Analysts’ price target is €77.36)

Showing 1 to 2 of 2 entries

Fresenius SE (FRE.DE) Frequently Asked Questions

What is Fresenius SE stock symbol?

Fresenius SE is a OTC stock, trading under the symbol FRE.DE (previously FRE-GR on Stockchase) on the Frankfurt Stock Exchange (FRE-GY). It is usually referred to as XETR:FRE or FRE.DE

Is Fresenius SE a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on FRE.DE (previously FRE-GR on Stockchase) on Stockchase. Read the latest expert commentary for Fresenius SE .

Is Fresenius SE a good investment or a top pick?

Fresenius SE was recommended as a Top Pick by Darren Sissons on 2018-07-31. Read the latest stock experts ratings for Fresenius SE .

Why is Fresenius SE stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Fresenius SE .

Is Fresenius SE worth watching?

Fresenius SE is covered by Stockchase experts and is worth watching.

What is Fresenius SE stock price?

On 2024-08-29, Fresenius SE (FRE.DE) stock closed at a price of $33.24.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Fresenius SE (FRE.DE)